+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antispasmodics Drugs Market by Class, Route, Distribution Channel, Application, Formulation, Mechanism, End User - Global Forecast to 2030- Product Image
Antispasmodics Drugs Market by Class, Route, Distribution Channel, Application, Formulation, Mechanism, End User - Global Forecast to 2030- Product Image
Sale

Antispasmodics Drugs Market by Class, Route, Distribution Channel, Application, Formulation, Mechanism, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5336390
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antispasmodics Drugs Market grew from USD 14.70 billion in 2024 to USD 15.95 billion in 2025. It is expected to continue growing at a CAGR of 8.39%, reaching USD 23.85 billion by 2030.

Setting the Stage for Antispasmodic Therapies

Antispasmodic therapies have become a cornerstone in the management of muscular spasms and functional disorders across gastrointestinal, gynecological, and urinary systems. As chronic conditions such as irritable bowel syndrome and dysmenorrhea affect millions globally, the demand for effective spasm-relief agents is surging. Advances in pharmacological science, coupled with evolving regulatory frameworks, have catalyzed innovation in both natural and synthetic antispasmodic compounds.

This analysis offers a comprehensive exploration of the antispasmodic drugs market, uniting clinical insights with commercial imperatives. By spotlighting the interplay between drug classes, delivery routes, and therapeutic applications, the report equips stakeholders with a clear understanding of market drivers and barriers. Whether you are a pharmaceutical leader seeking to refine your R&D portfolio or an investor evaluating growth potential, this executive summary distills critical developments and strategic imperatives essential for informed decision-making.

Evolving Trends Shaping Antispasmodic Market

The landscape of antispasmodic drugs is undergoing transformative shifts driven by personalized medicine, patient-centric delivery systems, and regulatory recalibrations. Manufacturers are harnessing pharmacogenomics to optimize dosing regimens and minimize adverse effects, while formulation scientists are pioneering extended-release gels and transdermal patches to enhance patient adherence.

At the same time, natural extracts are gaining traction alongside synthetic molecules, reflecting a broader demand for holistic treatment modalities. Regulatory agencies are streamlining approval pathways for breakthrough therapies, encouraging accelerated development of novel calcium channel blockers and GABA agonists. In parallel, digital health platforms are enabling remote monitoring of symptom severity and medication compliance, reshaping the treatment paradigm for chronic spasm-related disorders.

Assessing 2025 Tariff Impacts on US Antispasmodic Supply Chain

The introduction of enhanced tariffs in the United States scheduled for 2025 has significant implications for the antispasmodic supply chain. Active pharmaceutical ingredients sourced primarily from Asia will face increased import costs, exerting upward pressure on the production budgets of both generic and branded manufacturers. As excipients and raw materials become more expensive, companies must revisit their procurement strategies and assess the viability of domestic versus offshore manufacturing.

Supply chain resilience emerges as a critical priority, driving partnerships with regional API suppliers and investment in alternate logistic routes. Payers and healthcare providers are bracing for potential price adjustments, prompting negotiations around value-based contracts and formulary inclusions. Industry leaders will need to deploy a mix of cost mitigation measures, including vertical integration and collaborative procurement consortia, to sustain competitive pricing and maintain market access under the new tariff regime.

Decoding Market Segmentation Drivers for Targeted Growth

Understanding the nuances of market segmentation is essential to uncovering pockets of growth within the antispasmodic domain. The divide between natural and synthetic classes underscores divergent R&D trajectories, as formulators balance efficacy with consumer preference for botanical extracts. Delivery route preferences vary substantially across patient populations, with oral tablets dominating, while the parenteral category bifurcates into intramuscular and intravenous administrations and topical applications evolve into creams, gels, and patches that maximize localized relief.

The choice of distribution channel-from hospital pharmacies to online outlets and retail chains-reflects shifting purchasing behaviors influenced by convenience and reimbursement policies. Therapeutic application defines the focus of product development, as gastrointestinal indications such as spastic colon, irritable bowel syndrome, and peptic ulcer drive volume, while gynecological conditions like dysmenorrhea and endometriosis, alongside urinary disorders such as cystitis and overactive bladder, shape niche segments.

Formulation innovation remains a key differentiator, with capsules ranging from hard shell to soft gels and injections tailored for intramuscular, intravenous, or subcutaneous use. Syrups address pediatric and geriatric requirements, while tablets, whether coated or uncoated, deliver predictable release profiles. Mechanistic diversity-spanning anticholinergics categorized into quaternary and tertiary amines, calcium channel blockers split between dihydropyridines and non-dihydropyridines, and GABA agonists-fuels competitive positioning. Finally, the end user environment, from clinics and hospitals to homecare settings that include nurse assisted care or self-medication, dictates product packaging and patient support services.

Regional Dynamics Driving Market Expansion

Regional variations in healthcare infrastructure, regulatory frameworks, and patient demographics are shaping the competitive dynamics of the antispasmodic market. In the Americas, high healthcare expenditure and robust reimbursement systems support the adoption of premium formulations and innovative delivery platforms. Market consolidation among major pharmacy chains and increasing telehealth penetration are further expanding access to prescription antispasmodics.

Across Europe, the Middle East & Africa, stringent regulatory standards coexist with diverse national policies. Western Europe’s emphasis on clinical evidence and real-world data drives uptake of differentiated products, while emerging markets in Africa and the Gulf Cooperation Council countries are focused on enhancing supply chain reliability and local manufacturing capabilities. Parallel initiatives to strengthen pharmacovigilance and patient education are accelerating market growth.

The Asia-Pacific region represents a dual narrative of mature markets in Japan and Australia, characterized by incremental innovation and generics proliferation, alongside high-growth economies in China, India, and Southeast Asia. Cost containment pressures in public health systems encourage the use of cost-effective synthetic molecules, even as demand for natural antispasmodics rises. Cross-border collaborations and free trade agreements are streamlining regulatory pathways, further invigorating regional expansion.

Competitive Landscape and Leading Players Analysis

The competitive landscape is defined by a mix of global pharmaceutical giants and specialized players focusing on antispasmodic innovation. Leading multinationals are leveraging expansive R&D budgets to explore next-generation calcium channel blockers and novel GABA agonists, while mid-sized firms differentiate through niche natural extracts and rapid commercialization of generic portfolios.

Strategic alliances between formulators and contract development organizations are accelerating product launches, with an emphasis on scalable manufacturing and regulatory compliance. Several key players are forging partnerships with digital health start-ups to integrate symptom-tracking apps and teleconsultation services into their patient support programs. In parallel, targeted acquisitions in emerging markets are enhancing distribution networks and reinforcing local market penetration. The cumulative effect is a dynamic market where agility and strategic foresight drive competitive advantage.

Strategic Imperatives for Industry Leadership

Industry leaders must prioritize R&D allocation toward innovative mechanisms that address unmet therapeutic needs and minimize side effects. Strategic diversification of supply chains will safeguard against tariff volatility, encouraging collaboration with regional API manufacturers and investment in localized production facilities. Embracing digital health solutions-such as remote monitoring and adherence-enhancing technologies-will bolster patient engagement and differentiate product offerings.

Forging partnerships across the value chain, from contract development organizations to specialty pharmacies, can accelerate time-to-market while ensuring regulatory compliance. Expanding presence in high-growth regions through targeted alliances and licensing agreements will capitalize on emerging demand. Finally, adopting flexible pricing models and value-based agreements with payers will sustain market access and support long-term revenue growth.

Rigorous Methodology Ensuring Robust Insights

This analysis is underpinned by a rigorous methodology that synthesizes primary and secondary research. Expert interviews with pharmaceutical executives, clinicians, and key opinion leaders provided qualitative insights into therapeutic trends and market dynamics. A comprehensive review of regulatory filings, clinical trial registries, and patent databases offered a granular view of innovation pipelines.

Quantitative data were drawn from industry databases, government health statistics, and trade associations, ensuring robust statistical validation. Segmentation was conducted through a combination of market share analysis and consumption patterns, while regional mapping incorporated macroeconomic indicators and healthcare expenditure metrics. Triangulation across multiple sources and peer benchmarking exercises reinforced the credibility and reliability of the findings.

Synthesis of Market Insights and Future Outlook

The antispasmodic drugs market is at an inflection point, shaped by tariff pressures, segmentation complexity, and dynamic regional trends. Stakeholders equipped with granular insights into class distinctions, delivery formats, and therapeutic applications will be best positioned to capture emerging opportunities. Regulatory evolution and patient-centric innovations are redefining competitive benchmarks, demanding agility and strategic foresight.

As key players navigate supply chain realignments and pricing constraints, the ability to integrate digital health, forge collaborative partnerships, and tailor offerings to regional needs will determine market leadership. The consolidated findings and actionable recommendations presented herein chart a clear pathway for sustainable growth and enduring competitive advantage in the antispasmodic landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Class
    • Natural
    • Synthetic
  • Route
    • Oral
    • Parenteral
      • Intramuscular
      • Intravenous
    • Topical
      • Cream
      • Gel
      • Patch
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Application
    • Gastrointestinal Disorders
      • Irritable Bowel Syndrome
      • Peptic Ulcer
      • Spastic Colon
    • Gynecological Disorders
      • Dysmenorrhea
      • Endometriosis
    • Urinary Disorders
      • Cystitis
      • Overactive Bladder
  • Formulation
    • Capsule
      • Hard Shell
      • Soft Gel
    • Injection
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Syrup
    • Tablet
      • Coated
      • Uncoated
  • Mechanism
    • Anticholinergics
      • Quaternary Amine
      • Tertiary Amine
    • Calcium Channel Blockers
      • Dihydropyridines
      • Non Dihydropyridines
    • GABA Agonists
  • End User
    • Clinics
    • Homecare
      • Nurse Assisted Care
      • Self Medication
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A.
  • Almirall, S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Limited
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antispasmodics Drugs Market, by Class
8.1. Introduction
8.2. Natural
8.3. Synthetic
9. Antispasmodics Drugs Market, by Route
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.4. Topical
9.4.1. Cream
9.4.2. Gel
9.4.3. Patch
10. Antispasmodics Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Antispasmodics Drugs Market, by Application
11.1. Introduction
11.2. Gastrointestinal Disorders
11.2.1. Irritable Bowel Syndrome
11.2.2. Peptic Ulcer
11.2.3. Spastic Colon
11.3. Gynecological Disorders
11.3.1. Dysmenorrhea
11.3.2. Endometriosis
11.4. Urinary Disorders
11.4.1. Cystitis
11.4.2. Overactive Bladder
12. Antispasmodics Drugs Market, by Formulation
12.1. Introduction
12.2. Capsule
12.2.1. Hard Shell
12.2.2. Soft Gel
12.3. Injection
12.3.1. Intramuscular
12.3.2. Intravenous
12.3.3. Subcutaneous
12.4. Syrup
12.5. Tablet
12.5.1. Coated
12.5.2. Uncoated
13. Antispasmodics Drugs Market, by Mechanism
13.1. Introduction
13.2. Anticholinergics
13.2.1. Quaternary Amine
13.2.2. Tertiary Amine
13.3. Calcium Channel Blockers
13.3.1. Dihydropyridines
13.3.2. Non Dihydropyridines
13.4. GABA Agonists
14. Antispasmodics Drugs Market, by End User
14.1. Introduction
14.2. Clinics
14.3. Homecare
14.3.1. Nurse Assisted Care
14.3.2. Self Medication
14.4. Hospitals
15. Americas Antispasmodics Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Antispasmodics Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Antispasmodics Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Boehringer Ingelheim International GmbH
18.3.2. Sanofi S.A.
18.3.3. Almirall, S.A.
18.3.4. Teva Pharmaceutical Industries Ltd.
18.3.5. Viatris Inc.
18.3.6. Sandoz International GmbH
18.3.7. Pfizer Inc.
18.3.8. Dr. Reddy's Laboratories Limited
18.3.9. Sun Pharmaceutical Industries Ltd.
18.3.10. Glenmark Pharmaceuticals Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ANTISPASMODICS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTISPASMODICS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTISPASMODICS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ANTISPASMODICS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. ANTISPASMODICS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTISPASMODICS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY NATURAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PEPTIC ULCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPASTIC COLON, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HARD SHELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SOFT GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY UNCOATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY QUATERNARY AMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TERTIARY AMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DIHYDROPYRIDINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY NON DIHYDROPYRIDINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY NURSE ASSISTED CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SELF MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 108. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 109. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 110. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 111. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 112. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 115. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 117. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 119. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 120. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 121. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 122. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 123. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 124. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 126. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 129. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 130. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 136. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 138. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 139. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 140. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 218. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 219. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 220. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 221. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 224. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 225. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 226. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 227. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 228. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 229. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 230. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 231. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 232. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 235. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 236. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 237. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 238. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 239. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 242. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 243. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 244. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 245. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 246. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 247. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 248. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 249. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 250. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 251. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 271. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 272. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 273. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 274. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 275. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 278. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 279. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 280. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 281. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 282. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 283. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 284. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 285. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 286. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 287. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. ITALY ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 289. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 290. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 291. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 292. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 293. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 295. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 296. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 297. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 298. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 299. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 300. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 301. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 302. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 303. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 304. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 305. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 326. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 328. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 332. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2030 (USD MILLION)
TABLE 334. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 336. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA ANTISPASM

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antispasmodics Drugs market report include:
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A.
  • Almirall, S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Limited
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 15.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 23.85 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antispasmodics Drugs Market Report 2025 - Product Image

Antispasmodics Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Quadriplegia Treatment Market Report 2025 - Product Image

Quadriplegia Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hyoscine - Global Strategic Business Report - Product Image

Hyoscine - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Cerebral Palsy Treatment Market by Treatment Type, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030 - Product Image

Cerebral Palsy Treatment Market by Treatment Type, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Spinal Pumps Market by Product Type, End User, Indication, Technology, Distribution Channel - Global Forecast to 2030 - Product Image

Spinal Pumps Market by Product Type, End User, Indication, Technology, Distribution Channel - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From

About the Muscle Spasm Drug Market

The Muscle Spasm Drug market is a subset of the Central Nervous System Drugs market. It includes drugs used to treat muscle spasms, which are involuntary contractions of the muscles. These drugs are used to reduce pain and discomfort associated with muscle spasms, as well as to improve mobility. Commonly used muscle spasm drugs include muscle relaxants, antispasmodics, and anticonvulsants. These drugs are typically prescribed by a physician and are available in both oral and injectable forms. The Muscle Spasm Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, GlaxoSmithKline, Merck, and Sanofi. Other companies in the market include AbbVie, AstraZeneca, Teva Pharmaceuticals, and Mylan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.